

Special Issue

Precision Medicine in Radiomics and Radiogenomics

Message from the Guest Editor

Imaging plays an essential role in precision medicine, because it allows screening, early diagnosis, response evaluation, and recurrence assessment. A field that shows great promise in this context is radiomics, i.e., the process of extracting mineable, high-dimensional data from routine, standard of care images to provide an “imaging phenotype” for scoring, categorizing, and classifying disease severity, predicting response to therapy and patient outcome. The further correlation of imaging phenotype with gene expressions is known as radiogenomics, and it will serve as the foundation for surveillance of disease manifestation in terms of occurrence, location, extent, severity, and discovery of genetic polymorphisms. This Special Issue of the *Journal of Personalized Medicine* aims to delineate present and future perspectives of Radiomics and Radiogenomics in the era of precision medicine to better outline the increasingly prominent role of imaging in the management of complex, genetically heterogeneous diseases in oncology and non-oncological conditions.

Guest Editor

Dr. Serena Monti

Istituto di Biostrutture e Bioimmagini, Consiglio Nazionale delle Ricerche, 80125 Naples, Italy

Deadline for manuscript submissions

closed (10 May 2023)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/si/120706

*Journal of Personalized
Medicine*
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/journal/

[jpm](https://jpm.mdpi.com)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).